Companies › Ganzhou Hemay Pharmaceutical
2 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Hemay005 Phosphodiesterase 4 (PDE4) inhibitor | PDE4A, PDE4B, PDE4C, PDE4D | Phase 3 | Behçet's Disease; Moderate to Severe Ulcerative Colitis; Psoriasis | Dec 2026 |
| Hemay181 | – | Phase 1 | Solid Tumor; Advanced Solid Tumors | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06376474 | Hemay005 | Phase 1 | Psoriasis | Immunology | Dec 2025 |
| NCT05749432 | Hemay181 | Phase 1 | Solid Tumor | Oncology | Jan 2026 |
| NCT06145893 | Hemay005 | Phase 3 | Behçet's Disease | Immunology | May 2026 |
| NCT05486104 | Hemay005 | Phase 2 | Moderate to Severe Ulcerative Colitis | Immunology | Dec 2026 |
| NCT07446816 | Hemay181 | Phase 1 | Advanced Solid Tumors | Oncology | Aug 2027 |
Integrative Skin Science and Research Arcutis Biotherapeutics Palisade Bio Antengene Biologics Molecure
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.